Biotech News - Abraxis BioScience, Inc. (Public, NASDAQ:ABBI)

Abraxis BioScience, Inc. (Public, NASDAQ:ABBI)

Abraxis BioScience Launches New Abraxane Patient Assistance Program
Comprehensive Program Provides Access to Care for Cancer Patients

Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global
biopharmaceutical company today announced the launch of the Abraxis
Patient Access Program (APAP), a comprehensive patient assistance
program for cancer patients being treated with ABRAXANE® (paclitaxel
protein-bound particles for injectable suspension) (albumin-bound).
Through APAP, financially eligible cancer patients in need of
treatment with ABRAXANE will receive access to the drug at no cost.
This new program, which replaces the previous ABRAXANE patient
assistance programs, makes it possible for financially eligible
cancer patients to receive assistance in all instances where
ABRAXANE has been prescribed.

"Through our new patient assistance program, we will be able to
provide eligible cancer patients with ABRAXANE at no cost," said
Patrick Soon-Shiong, chairman and chief executive officer of Abraxis
BioScience. "Since its launch in 2005, over 20,000 patients with
cancer have received ABRAXANE. With nearly 1.4 million people in the
United States estimated to be diagnosed with cancer in 2006, it is
important for patients to be able to receive the best possible
treatment. We are committed to ensuring there are no cost barriers
for cancer patients who may benefit from treatment with ABRAXANE."

Access to this program is available through the Abraxis Resource
Center (ARC of Support), a comprehensive program that provides a
broad range of services caring for patients being treated with
ABRAXANE. This new program offers two distinct access points for
cancer patients:

ABRAXANE at no cost to eligible uninsured patients with a household
adjusted gross income of less than $75,000 per year.
Replacement of ABRAXANE at no cost for physicians treating an
eligible insured patient, who requires additional financial support
following a denied insurance claim.
"Since the FDA approval of ABRAXANE in January 2005, we have
provided reimbursement and product information support for
physicians and their patients. Our dedication to this endeavor has
not wavered. With the launch of this new program, we are now able to
provide expanded reimbursement support to more cancer patients,"
said Carlo Montagner, president of Abraxis Oncology, a division of
Abraxis BioScience.

Physicians who wish to enroll a patient in the program should call
the ARC of Support at 1-800-564-0216, option three. For more
information about ABRAXANE and the services provided by ARC of
Support including APAP, please visit www.abraxane.com.

About Breast Cancer

According to the American Cancer Society, breast cancer is the most
common cancer among women, other than skin cancer, and is the second
leading cause of cancer death in women in the United States. The
risk of having breast cancer for a woman sometime during her life is
about one in eight. In 2006 alone, an estimated 213,000 new cases of
breast cancer are expected to occur in women, and an estimated
41,000 women are expected to die from the disease.

About ABRAXANE®

The U.S. Food and Drug Administration approved ABRAXANE® for
Injectable Suspension (paclitaxel protein-bound particles for
injectable suspension) (albumin-bound) in January 2005 for the
treatment of breast cancer after failure of combination chemotherapy
for metastatic disease or relapse within six months of adjuvant
chemotherapy. Prior therapy should have included an anthracycline
unless clinically contraindicated. For the full prescribing
information for ABRAXANE® please visit www.abraxane.com.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical
company dedicated to meeting the needs of critically ill patients.
The company develops, manufactures and markets one of the broadest
portfolios of injectable products and leverages revolutionary
technology such as its nab™ platform to discover and deliver
breakthrough therapeutics that transform the treatment of cancer and
other life-threatening diseases. The first FDA approved product to
use this nab platform, ABRAXANE®, was launched in 2005 for the
treatment of metastatic breast cancer. Abraxis trades on the NASDAQ
Stock Market under the symbol ABBI. For more information about the
company and its products, please visit www.abraxisbio.com.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/